The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Skin Health

S-Biomedic Completes Series A Round With DSM Venturing
Finance

S-Biomedic Completes Series A Round With DSM Venturing

FEB 18, 2019
Azitra’s Clinical Study of AZT-04 for Cosmetic Use Completes Enrolment
Pharma & Human Health

Azitra’s Clinical Study of AZT-04 for Cosmetic Use Completes Enrolment

FEB 1, 2019
AOBiome Expands Intellectual Property Estate with U.S. Patent for Use of Ammonia Oxidizing Bacteria for the Treatment of Eczema
Pharma & Human Health

AOBiome Expands Intellectual Property Estate with U.S. Patent for Use of Ammonia Oxidizing Bacteria for the Treatment of Eczema

JAN 6, 2019
Conference Summary: Microbiome Movement Skin Health & Dermatology
Pharma & Human Health

Conference Summary: Microbiome Movement Skin Health & Dermatology

SEP 28, 2018
The Jackson Laboratory and Azitra Receive Department of Defense Grant: Bioengineered Commensals to Fight Staphylococcus Aureus
Finance

The Jackson Laboratory and Azitra Receive Department of Defense Grant: Bioengineered Commensals to Fight Staphylococcus Aureus

SEP 17, 2018
Beiersdorf takes an equity investment into S-Biomedic and collaborates on the skin microbiome
Finance

Beiersdorf takes an equity investment into S-Biomedic and collaborates on the skin microbiome

JUL 20, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
Clinical & Manufacturing

Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis

MAY 25, 2018
Azitra Secures $2.15 Million Convertible Debt Financing Led Jointly by Bios Partners and Connecticut Innovations
Finance

Azitra Secures $2.15 Million Convertible Debt Financing Led Jointly by Bios Partners and Connecticut Innovations

MAY 2, 2018